AUTL Stock Summary and Trading Ideas (Autolus Therapeutics PLC - American Depositary Shares | NASDAQ:AUTL)

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.

As of January 28, 2026, AUTL stock price climbed to $1.45 with 1,516,311 million shares trading.

AUTL has a beta of 1.19, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.07 to the broad based SPY ETF.

AUTL has a market cap of $385.59 million. This is considered a Small Cap stock.

Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $21 million in Revenue and -$.30 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.07.

In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.

The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, GWX, QQQS, IBBQ, BIB.

AUTL has underperformed the market in the last year with a return of -35.8%, while the SPY ETF gained +17.2%. In the last 3 month period, AUTL fell short of the market, returning -12.1%, while SPY returned +1.8%. However, in the most recent 2 weeks AUTL has outperformed the stock market by returning +5.8%, while SPY returned +0.2%.

AUTL support price is $1.34 and resistance is $1.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.